CPX-351 (Vyxeos) is a liposomal formulation of cytarabine and daunorubicin with potential antitumor activity. CPX-351 delivers these two compounds to leukemia cells in a synergistic 5:1 ratio, with higher delivery rates than in normal bone marrow cells. CPX-351 is indicated for the treatment of acute myeloid leukemia.
Molecular Weight:
770.74
Purity:
98.95%
CAS Number:
[1256639-86-7]
Formula:
C36H42N4O15
Target:
Others
T31088
* VAT and and shipping costs not included. Errors and price changes excepted